FDA Approves Clonidine XR: First Liquid Non-Stimulant for ADHD

The landscape of ADHD (Attention Deficit Hyperactivity Disorder) treatment has been notably transformed with the FDA’s recent approval of Clonidine XR, marking a significant milestone as the first liquid non-stimulant medication available for managing ADHD symptoms. This development promises to provide a new avenue of relief for those who struggle with ADHD, particularly children and individuals who have difficulty swallowing pills.

Traditionally, the treatment for ADHD has predominantly relied on stimulant medications, such as methylphenidate (Ritalin) and amphetamine-based drugs (Adderall), which have shown substantial efficacy in managing symptoms.

However, stimulant medications are not without their drawbacks. Some patients experience side effects like insomnia, decreased appetite, and increased heart rate. Additionally, there is a potential for misuse and dependency. For those who cannot tolerate stimulants or do not respond well to them, non-stimulant options like atomoxetine (Strattera) and guanfacine (Intuniv) have been available. Yet, until now, there has been a lack of liquid non-stimulant formulations, posing challenges for certain patient populations.

FDA Approves Clonidine XR: The First Liquid Non-Stimulant for ADHD

Psychiatry Education Forum Academy’s Dr. Harvinder Singh has summarized Clonidine XR (Onyda XR) in the following sections:

(1) FDA Indication
(2) Mechanism of Action
(3) Clonidine vs Guanfacine
(4) Understanding Dosing & Titration
(5) How to Discontinue?
(6) Specific Administration Instructions
(7) Switching from IR to XR formulation
(8) Warnings & Precautions
(9) Important Drug Interactions

Here is one slide from this presentation, explaining on how to dose and titrate Clonidine XR for ADHD:

WATCH YOUTUBE VIDEO FOR DETAILS:

FOR ACADEMY MEMBERS:

Clonidine XR (Liquid): FDA Approved for ADHD

ACADEMY

INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?

JOIN ACADEMY MEMBERSHIP:

This is a closed membership for medical professionals only.

  • 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
  • Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
  • Goal: is to have all important clinically relevant topics in one place for ease of access.
GENERAL
$ 150/YR
  •  
STUDENTS
$ 99/YR
  •  

DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.

Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com

© 2024 All Rights Reserved.

Related Articles